FDA Places Clinical Hold on Gilead's Weekly HIV Combination Therapy Following Safety Signal
Key Insights
The FDA has placed a clinical hold on five Gilead HIV (search) trials involving weekly combination therapy GS-1720 and GS-4182 after safety signals showed decreased CD4+ T-cell (search) and lymphocyte counts in some patients.
The hold affects two Phase II/III WONDERS trials comparing the weekly combo to Biktarvy in both treatment-naive and virologically suppressed HIV (search) patients, plus three Phase I studies.
Analysts expect no impact on the pending June 19 FDA decision for lenacapavir's HIV (search) prevention indication, as GS-4182 is a different pro-drug formulation than the approved Sunleca (search) version.
The FDA has placed a clinical hold on five Gilead Sciences trials evaluating an investigational weekly HIV (search) combination therapy after safety signals emerged showing decreased immune cell counts in some patients. The hold affects the company's development of GS-1720, an integrase strand transfer inhibitor (search), combined with GS-4182, a capsid inhibitor (search), but analysts say it will not impact the pending regulatory decision for lenacapavir's HIV prevention indication.
Safety Signal Prompts Regulatory Action
Gilead announced Tuesday that the FDA placed the clinical hold after identifying decreases in CD4+ T-cell (search) and absolute lymphocyte counts in a subset of participants receiving both investigational drugs. These immune cell reductions can signal a weakened immune system in HIV (search) patients, prompting the regulatory pause.
The hold encompasses two Phase II/III trials—WONDERS-1 and WONDERS-2—along with three Phase I studies. WONDERS-1 is comparing the weekly combination therapy with Gilead's approved HIV (search) medicine Biktarvy in people with HIV who are virologically suppressed, while WONDERS-2 features the same comparison in treatment-naive patients.
"Clinical trial investigators involved in the trials have been informed of these actions," Gilead stated. "We intend to investigate and pursue the potential of both agents and are committed to working with regulatory authorities to resolve the issues underlying the clinical hold."
No Impact Expected on Lenacapavir Decision
Despite the hold, Jefferies analysts emphasized that the pause should not affect the FDA's pending June 19 decision on lenacapavir for HIV (search) pre-exposure prophylaxis (PrEP). While GS-4182 is a pro-drug formulation related to lenacapavir, the PrEP indication represents a different therapeutic application with distinct safety and efficacy profiles.
"While it might increase some investor uncertainty into the all-important June 19 PDUFA for lenacapavir for PrEP, we see no major read-through and expect an on-time and clean FDA approval," Jefferies analysts wrote.
BMO Capital Markets agreed with this assessment but noted that Gilead's shares could face pressure as investors process the news. The company's stock declined 2% to $110.75 following the announcement.
Broader HIV Pipeline Remains Intact
Gilead stressed that the clinical hold does not impact other assets in its HIV (search) development pipeline. The company has multiple long-acting oral and injectable investigational HIV treatment combinations under evaluation, including regimens with weekly, monthly, quarterly, and twice-yearly dosing schedules.
Jefferies analysts noted that if the FDA had broader safety concerns, it would have likely stalled additional Gilead formulations and integrase inhibitors currently in development. The firm places particular weight on Phase I data for lenacapavir combined with injectable integrase inhibitors GS-1219 and GS-3242, with Gilead planning to select one of these combinations by year-end.
Historical Context and Market Implications
Similar safety signals have emerged in HIV (search) drug development previously. Merck (search)'s Isentress faced FDA holds after CD4 T-cell count reductions were observed, and a combination of Isentress with Gilead's lenacapavir was also placed on hold several years ago before ultimately being released in 2022 using lower doses.
Gilead is seeking to expand its HIV (search) franchise, which is anchored by Biktarvy—a drug that recorded $13.4 billion in sales in 2024. The company aims to launch nine new HIV drugs by 2033, with lenacapavir's PrEP indication representing a significant opportunity. BMO predicts peak sales of $6.5 billion for the prevention indication, backed by Phase III data showing 100% efficacy in cisgender women and 96% reduction in HIV incidence in a diverse population including cisgender men, transgender individuals, and nonbinary people.
"The safety of individuals taking Gilead medicines is our foremost priority and we remain focused on pursuing advances to improve outcomes and expand options for people living with HIV (search)," the company stated.